LGALS1 and T-cell non-Hodgkin lymphoma: For example, increased Gal-1 serum levels have already been demonstrated in a number of systemic, non-central nervous system malignancies including head and neck squamous cell carcinoma [51], lung cancer [52], T cell lymphoma [53], classical Hodgkin lymphoma [54], and benign thyroid tumors [55].